^
Association details:
| Biomarker: | EGFR L858R + EGFR T790M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Published date:
02/03/2020
Excerpt:
...we randomized EGFRT790M/L858R mice (after 8 weeks of doxycycline treatment) in 4 treatment groups: (i) vehicle (control), (ii) gefitinib, (iii) DBZ, and (iv) gefitinib plus DBZ…gefitinib alone did not have any antitumor effect in EGFRT790M/L858R mice (52% of lung was tumor tissue).
DOI:
10.1172/JCI126896
Source:
Title:
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Published date:
02/03/2020
Excerpt:
CONTRADICTING EVIDENCE:...we randomized EGFRT790M/L858R mice (after 8 weeks of doxycycline treatment) in 4 treatment groups: (i) vehicle (control), (ii) gefitinib, (iii) DBZ, and (iv) gefitinib plus DBZ…gefitinib alone did not have any antitumor effect in EGFRT790M/L858R mice (52% of lung was tumor tissue). Conversely, the DBZ plus gefitinib combination led to a very significant reduction of the tumor area compared with DBZ alone (tumor tissue covered only 10% of the total lung area)...
Secondary therapy:
Notch Inhibitor
DOI:
10.1172/JCI126896
